Miltenyi Biotec joins EMBL’s Corporate Partnership Programme

Home  >>  News  >>  Miltenyi Biotec joins EMBL’s Corporate Partnership Programme

Miltenyi Biotec joins EMBL’s Corporate Partnership Programme

On January 18, 2019, Posted by , In News, By , , With Comments Off on Miltenyi Biotec joins EMBL’s Corporate Partnership Programme

Joining forces to advance training in biomedical research and therapy

EMBL and Miltenyi Biotec, a global provider of products and services that advance biomedical research and cellular therapy from basic and translational research to clinical application, have teamed up in the EMBL Advanced Training Centre Corporate Partnership Programme to advance research in the life sciences.

“Miltenyi Biotech has a long tradition of providing novel tools for state-of-the-art cell biology and accompanying this with a dedicated training scheme,” says Malte Paulsen, Head of EMBL’s Flow Cytometry Core Facility. “Miltenyi becoming a partner in the Corporate Partnership Programme will strengthen EMBL’s efforts to provide the best possible training on various topics in cell phenotyping, purification and targeted modification, from basic research to adaptive medicine. Knowledge is best transferred if real experience is backing it up.”

“EMBL is the ideal partner for Miltenyi Biotec, as we share the same spirit of conducting groundbreaking research and giving the life science community access to the knowledge gained and the associated tools,” says Oliver Burlon, vice-president of Miltenyi’s MACS Services Business Unit. “Training is the key factor to leverage on these advancements and therefore this new partnership will bring new attractive offerings to researchers in Europe.”

Original News.

Related Post

Comments are closed.